Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept.

    Nucl Med Mol Imaging 2018 Feb 11;52(1):80-81. Epub 2018 Jan 11.
    1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
    The dose-limiting salivary gland toxicity ofAc-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer remains unresolved. Suppressing the metabolism of the gland by intraparenchymal injections of botulinum toxin appears to be a promising method to reduce off-target uptake. AGa-PSMA PET/CT scan performed 45 days after injection of 80 units of botulinum toxin A into the right parotid gland in a 63-year-old patient showed a decrease in the SUVmean in the right parotid gland of up to 64% as compared with baseline. This approach could be a significant breakthrough for radioprotection of the salivary glands during PSMA radioligand therapy.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1007/s13139-017-0508-3DOI ListingPossible
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777965PMCFound

    Similar Publications

    177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    J Nucl Med 2016 07 21;57(7):1006-13. Epub 2016 Jan 21.
    Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany.
    Unlabelled: The objective of this study was to analyze the safety and efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

    Methods: Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA. (68)Ga-PSMA-(N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid) ((68)Ga-PSMA) PET/CT was used for patient selection and follow-up after PSMA RLT. Read More
    Radiation Dosimetry forLu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.
    J Nucl Med 2017 Mar 22;58(3):445-450. Epub 2016 Sep 22.
    Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
    Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed doses for normal organs and tumor lesions usingLu-PSMA I&T (I&T is imaging and therapy) in patients undergoing up to 4 cycles of radioligand therapy. Results were compared with pretherapeutic Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBEDCC)] (Ga-PSMA-HBED-CC) PET. Read More
    The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    J Nucl Med 2015 Nov 20;56(11):1697-705. Epub 2015 Aug 20.
    Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.
    Unlabelled: PET imaging with the prostate-specific membrane antigen (PSMA)-targeted radioligand (68)Ga-PSMA-11 is regarded as a significant step forward in the diagnosis of prostate cancer (PCa). More recently, a PSMA ligand was developed that can be labeled with (68)Ga, (111)In, (177)Lu, and (90)Y. This ligand, named PSMA-617, therefore enables both diagnosis and therapy of PCa. Read More
    Preliminary results on response assessment usingGa-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.
    Eur J Nucl Med Mol Imaging 2017 Nov 28. Epub 2017 Nov 28.
    Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
    Purpose: To investigate the value ofGa-HBED-CC PSMA (Ga-PSMA) PET/CT for response assessment in metastatic castration-sensitive and castration-resistant prostate cancer (mCSPC and mCRPC) during docetaxel chemotherapy.

    Methods: Ga-PSMA PET/CT was performed in seven mCSPC patients before and after six cycles of upfront docetaxel chemotherapy and in 16 mCRPC patients before and after three cycles of palliative docetaxel chemotherapy. Radiographic treatment response was evaluated separately on theGa-PSMA PET and CT datasets. Read More